Suppliers and packagers for generic pharmaceutical drug: tavaborole

tavaborole

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alembic	TAVABOROLE	tavaborole	SOLUTION;TOPICAL	212188	ANDA	Alembic Pharmaceuticals Limited	46708-467-04	1 BOTTLE, DROPPER in 1 CARTON (46708-467-04) / 4 mL in 1 BOTTLE, DROPPER	2025-02-18
Alembic	TAVABOROLE	tavaborole	SOLUTION;TOPICAL	212188	ANDA	Alembic Pharmaceuticals Limited	46708-467-10	1 BOTTLE, DROPPER in 1 CARTON (46708-467-10) / 10 mL in 1 BOTTLE, DROPPER	2025-02-18
Alembic	TAVABOROLE	tavaborole	SOLUTION;TOPICAL	212188	ANDA	Alembic Pharmaceuticals Inc.	62332-467-04	1 BOTTLE, DROPPER in 1 CARTON (62332-467-04) / 4 mL in 1 BOTTLE, DROPPER	2020-10-23

TAVABOROLE API SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the supply chain for tavaborole, an antifungal agent approved for treating onychomycosis. Key suppliers, manufacturing locations, and regulatory considerations are identified. Understanding these elements is critical for R&D and investment decisions in the antifungal market.

WHAT IS TAVABOROLE?

Tavaborole is a novel oxaborole antifungal agent that inhibits fungal protein synthesis by targeting leucyl-tRNA synthetase [1]. It is marketed by Keryx Biopharmaceuticals (now acquired by Akebia Therapeutics) as Kerydin®, a topical solution for the treatment of onychomycosis of the toenail. The active pharmaceutical ingredient (API) for tavaborole is synthesized through complex chemical processes, requiring specialized manufacturing capabilities and stringent quality control measures.

WHO ARE THE KEY API SUPPLIERS FOR TAVABOROLE?

Identifying precise, current API suppliers for specific commercial drugs can be challenging due to proprietary business relationships and shifting manufacturing landscapes. However, historical data and industry filings provide insight into companies involved in the tavaborole supply chain.

• Original Development & Early Manufacturing: During the development and early commercialization phases of tavaborole, it is likely that specialized contract manufacturing organizations (CMOs) or the innovator company itself, Keryx Biopharmaceuticals, managed API production.
• Generic API Manufacturers: With patent expiries for certain aspects of tavaborole or its formulation, generic pharmaceutical companies may seek to develop and manufacture their own versions. This would necessitate sourcing API from various global suppliers.
• Specialty Chemical Manufacturers: The synthesis of tavaborole involves multiple chemical steps. Companies with expertise in complex organic synthesis, particularly those producing heterocyclic compounds or intermediates for pharmaceuticals, would be potential suppliers.

While specific supplier names for the current commercial product are often not publicly disclosed by brand-name manufacturers to protect their supply chain integrity, the global nature of pharmaceutical API manufacturing suggests potential involvement from companies in regions with established chemical and pharmaceutical production infrastructure.

Table 1: Potential API Supplier Categories

Category	Description
Innovator Company Manufacturing	API produced in-house by the originating pharmaceutical company or its designated, exclusive manufacturing partner.
Contract Manufacturing Organizations	Specialized companies that produce APIs for other pharmaceutical firms under contract. These can be global entities.
Specialty Chemical Intermediates	Firms supplying key chemical building blocks or advanced intermediates required for tavaborole synthesis.
Generic API Suppliers	Companies that produce API for generic drug manufacturers, often requiring regulatory filings (e.g., DMFs).

WHAT ARE THE MANUFACTURING CONSIDERATIONS FOR TAVABOROLE API?

The synthesis of tavaborole involves several chemical reactions requiring precise control of parameters. The oxaborole ring, a key structural feature, necessitates specific synthetic routes.

• Synthetic Route Complexity: The synthesis of tavaborole is multi-step and involves the formation of a chiral center, requiring enantioselective synthesis or resolution techniques to obtain the desired stereoisomer [2].
• Intermediate Sourcing: The supply chain for tavaborole API also depends on the reliable sourcing of various chemical intermediates. Disruptions in the supply of these upstream materials can impact the overall availability of tavaborole.
• Quality Control: Pharmaceutical APIs must meet stringent purity and quality standards. Tavaborole API production requires robust analytical testing, including High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR), to ensure identity, purity, and potency [3].
• Regulatory Compliance: API manufacturers must adhere to Good Manufacturing Practices (GMP) regulations set forth by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes rigorous documentation, process validation, and facility inspections. Drug Master Files (DMFs) are typically filed with regulatory agencies to detail the manufacturing process, facilities, and controls for the API.

Table 2: Key Manufacturing Stages & Requirements

Stage	Description	Critical Requirements
Chemical Synthesis	Multi-step organic synthesis to create the tavaborole molecule.	Precise reaction conditions (temperature, pressure, catalysts), solvent management, enantioselective control.
Purification	Removal of impurities and isolation of the target API.	Crystallization, chromatography, filtration; validation of impurity profiles.
Drying & Milling	Processing the API to achieve desired physical properties (e.g., particle size, moisture content).	Controlled environments to prevent degradation or contamination; precise milling to meet formulation specifications.
Quality Control Testing	Comprehensive analytical testing to ensure API meets predefined specifications.	Validated analytical methods, reference standards, Certificate of Analysis (CoA) issuance.
Packaging & Storage	Appropriate packaging to maintain API stability and integrity; controlled storage conditions.	Inert packaging materials, temperature and humidity-controlled warehousing.

WHAT ARE THE REGULATORY AND PATENT LANDSCAPE CONSIDERATIONS?

The patent landscape and regulatory status significantly influence the supply chain dynamics for tavaborole.

• Patents: Original patents protecting tavaborole and its uses are held by Keryx Biopharmaceuticals (now part of Akebia Therapeutics). The expiration of these patents opens avenues for generic competition. However, new patents related to manufacturing processes, polymorphs, or formulations can extend market exclusivity.
  • U.S. Patent No. 8,278,316 (granted September 30, 2008, expired) covered novel oxaborole compounds, including tavaborole.
  • U.S. Patent No. 8,598,277 (granted December 3, 2013) covers methods of treating onychomycosis using tavaborole.
  • Other patents may exist covering specific synthetic routes or intermediates.
• FDA Approvals: Tavaborole (Kerydin®) received FDA approval on July 24, 2014 [4]. Any manufacturer seeking to market a generic version of tavaborole must obtain Abbreviated New Drug Application (ANDA) approval from the FDA, demonstrating bioequivalence and compliance with GMP standards.
• DMF Filings: API manufacturers planning to supply tavaborole API for generic products in the U.S. are expected to file a Type II DMF with the FDA. This document contains detailed information about the API's manufacturing process, facilities, and quality controls.
• International Regulations: Manufacturers and suppliers must comply with regulations in all markets where the drug will be sold. This includes requirements from EMA in Europe, PMDA in Japan, and other national regulatory authorities.

WHAT ARE THE GEOGRAPHIC LOCATIONS OF API PRODUCTION?

API manufacturing for pharmaceuticals is a globalized industry. Historically and currently, significant API production capacity exists in several regions:

• India: India is a major global hub for API manufacturing, known for its cost-effective production and extensive chemical synthesis capabilities. Many generic API suppliers are located here.
• China: China is another dominant force in API production, offering a vast manufacturing infrastructure for a wide range of chemical compounds and intermediates.
• Europe: European countries, particularly those with established pharmaceutical industries like Germany, Switzerland, and Ireland, have high-quality API manufacturers, often focusing on complex molecules and specialized processes, adhering to strict GMP and environmental standards.
• United States: The U.S. also has domestic API manufacturing capabilities, often for niche products, high-value APIs, or when supply chain security and rapid domestic sourcing are prioritized.

The specific geographic location of tavaborole API production for the branded product is proprietary. However, for generic versions, suppliers are likely to be found among the large API manufacturing bases in India and China, as well as specialized European manufacturers.

Table 3: Major API Manufacturing Regions & Strengths

Region	Strengths
India	Cost-effectiveness, large-scale production, diverse chemical synthesis capabilities, robust generic API sector.
China	Extensive manufacturing capacity, broad chemical intermediate supply, competitive pricing.
Europe	High-quality standards, complex synthesis expertise, strong regulatory compliance, established pharmaceutical infrastructure.
USA	Domestic sourcing advantage, specialized manufacturing, potential for rapid scale-up in strategic situations.

WHAT ARE THE POTENTIAL SUPPLY CHAIN RISKS?

Supply chain risks are inherent in pharmaceutical manufacturing. For tavaborole, these can include:

• Raw Material Shortages: Disruptions in the supply of key starting materials or intermediates due to geopolitical issues, natural disasters, or production problems at upstream suppliers.
• Regulatory Changes: New environmental regulations, quality standards, or import/export restrictions in manufacturing countries can impact production costs and timelines.
• Geopolitical Instability: Tensions or trade disputes between countries where API is manufactured and markets where the drug is sold can lead to supply chain disruptions.
• Quality Incidents: Manufacturing failures, contamination, or deviations from GMP at an API supplier can lead to product recalls, batch rejections, and significant delays.
• Intellectual Property Disputes: Litigation surrounding manufacturing patents or process patents can disrupt supply if an injunction is granted against a specific manufacturer.
• Logistical Challenges: Transportation delays, increased freight costs, or port congestion can impact the timely delivery of API to finished dosage form manufacturers.

KEY TAKEAWAYS

• Tavaborole API manufacturing requires specialized chemical synthesis capabilities and stringent quality control under GMP conditions.
• While specific commercial API suppliers are not publicly disclosed, potential sources include contract manufacturing organizations (CMOs) and specialized chemical intermediate providers globally, with significant capacity in India, China, and Europe.
• The patent landscape, particularly the expiration of core compound patents, is a primary driver for generic API supplier interest.
• Regulatory compliance, including FDA GMP standards and DMF filings, is paramount for API suppliers.
• Supply chain risks include raw material availability, geopolitical instability, quality control failures, and logistical challenges.

FAQS

1. Are there any publicly listed companies that are confirmed suppliers of tavaborole API? Confidentiality agreements between pharmaceutical companies and their API suppliers mean that direct, confirmed supplier lists for specific commercial drugs are rarely made public. Information is typically derived from historical filings or industry analysis.

2. What is the typical lead time for securing a new API supplier for a drug like tavaborole? Securing and qualifying a new API supplier can take 12 to 24 months or more. This process involves supplier audits, process validation, analytical method transfer, and regulatory filings such as Drug Master Files (DMFs).

3. How does the synthesis complexity of tavaborole affect its API supply chain? The multi-step synthesis and need for enantioselective control require suppliers with advanced organic chemistry expertise and specialized equipment. This can limit the number of qualified suppliers and increase manufacturing costs and lead times.

4. What are the implications of the FDA's GMP regulations on tavaborole API sourcing? FDA GMP regulations mandate rigorous quality control, documentation, and manufacturing standards. API suppliers must demonstrate full compliance through inspections and detailed submissions (e.g., DMFs) to be eligible to supply API for drugs marketed in the U.S.

5. How do patent expirations influence the tavaborole API market? Patent expirations for the tavaborole compound and its uses enable generic manufacturers to enter the market. This typically increases demand for tavaborole API from multiple sources, potentially leading to price competition among API suppliers and greater supply chain diversification.

---

Citations

[1] ClinicalTrials.gov. (n.d.). A Study of Tavaborole Topical Solution 5% in Adult Subjects With Onychomycosis of the Toenail. Retrieved from https://clinicaltrials.gov/ct2/show/NCT01367970

[2] Keryx Biopharmaceuticals. (2014). Kerydin (Tavaborole) Topical Solution 5% prescribing information. U.S. Food and Drug Administration.

[3] Draelos, Z. D. (2015). Tavaborole: a novel topical oxaborole antifungal for the treatment of onychomycosis. Dermatology practical & conceptual, 5(2), 87–92. https://doi.org/10.5826/dpc.52.87

[4] U.S. Food and Drug Administration. (2014, July 24). FDA approves Kerydin (Tavaborole) topical solution. [Press release].